73210-73-8
Chemical Structure
Xamoterol hemifumarate
Synonym(s): Corwin hemifumarate; ICI 118587 hemifumarate
- CAS No.: 73210-73-8
- Formula:C20H29N3O9
- Molecular Weight:397.43
SMILES: O=C(N1CCOCC1)NCCNCC(O)COC2=CC=C(O)C=C2.O=C(O)/C=C/C(O)=O
Biological Activity: Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Xamoterol hemifumarate | 98.18% | Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xamoterol hemifumarate (Standard) | ≥98% | Xamoterol hemifumarate (Standard) is the analytical standard of Xamoterol hemifumarate (HY-101327A). This product is intended for research and analytical applications. Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ikram H, et al. Xamoterol in severe heart failure. Lancet. 1990 Aug 25;336(8713):517-8. [Content Brief]
- [2]. Malta E, et al. The in vitro pharmacology of xamoterol (ICI 118,587). Br J Pharmacol. 1985;85(1):179-187. [Content Brief]
- [3]. Kowalski MT, et al. Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation. Br J Pharmacol. 1990;99(1):27-30. [Content Brief]
- [4]. Mehlsen J, et al. Xamoterol, a new selective beta-1-adrenoceptor partial agonist, in the treatment of postural hypotension. Acta Med Scand. 1986;219(2):173-177. [Content Brief]
- [5]. Hashimoto T, et al. The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest. Br J Clin Pharmacol. 1986;21(3):259-265. [Content Brief]
- [6]. Löfdahl CG, et al. Effects of xamoterol (ICI 118,587) in asthmatic patients. Br J Clin Pharmacol. 1984;18(4):597-601. [Content Brief]
- [7]. Jennings G, et al. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol. Clin Pharmacol Ther. 1984;35(5):594-603. [Content Brief]
